If lifestyle factors are the primary reason semaglutide did not work, switching to tirzepatide alone will not solve the problem
Pancreatic Beta Cell Dual Incretin Biology Research Tirzepatide drives glucose-stimulated insulin secretion through simultaneous GIPR and GLP-1R co-activation in pancreatic beta cells producing additive cAMP-PKA-EPAC2 pathway stimulation, KATP channel closure potentiation, and calcium-triggered insulin exocytosis enhancement through dual receptor engagement
Individual responses can vary, but many individuals begin to notice improvements in weight loss and blood sugar control within weeks of starting Tirzepatide
Study 1: This study highlighted that Semaglutide treatment resulted in an average weight loss of 10% among participants with Type 2 diabetes
Review your health history, weight loss challenges, goals, medications, lifestyle, and previous treatment attempts
Membership fees, consultation fees, and any filled medication are nonrefundable